<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01881347</url>
  </required_header>
  <id_info>
    <org_study_id>H-32036</org_study_id>
    <secondary_id>5P01HL068758-10</secondary_id>
    <nct_id>NCT01881347</nct_id>
  </id_info>
  <brief_title>Effects of Resveratrol on Endothelial Function in Type 2 Diabetes Mellitus</brief_title>
  <official_title>Randomized Crossover Study of The Effects of Resveratrol on Endothelial Function in Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study is designed to test the hypothesis that resveratrol supplementation will
      improve the function of the endothelium in patients with type 2 diabetes mellitus.

      The function of the endothelium will be tested with a non-invasive technique that uses
      ultrasound to measure the amount of dilation that occurs in the brachial artery following
      5-minute cuff occlusion. To help us understand potential mechanisms of benefit, we will also
      collect blood, urine, and cell samples and test the effects of treatment on protein
      expression, nitric oxide production, and function of mitochondria.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2013</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">March 1, 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Brachial artery flow mediated dilation</measure>
    <time_frame>2 hours, 2 weeks, and 4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Fingertip peripheral arterial tonometry</measure>
    <time_frame>2 hours, 2 weeks, and 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Carotid femoral pulse wave velocity</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Reactive hyperemia</measure>
    <time_frame>2 hours, 2 weeks, 4 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from Baseline in Serum glucose</measure>
    <time_frame>2 and 4 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from Baseline in Serum insulin</measure>
    <time_frame>2 and 4 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from Baseline in Mononuclear cell mitochondrial DNA damage</measure>
    <time_frame>4 weejs</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from Baseline in Mononuclear cell mitochondrial mass</measure>
    <time_frame>4 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from Baseline in Mononuclear cell mitochondrial production of reactive oxygen species</measure>
    <time_frame>4 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from Baseline in Endothelial cell gene expression</measure>
    <time_frame>4 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from Baseline in Endothelial cell protein expression</measure>
    <time_frame>4 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Active First</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active resveratrol first, placebo second</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo first</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo first, active resveratrol second</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Resveratrol</intervention_name>
    <description>Resveratrol 100 mg daily for 2 weeks followed by resveratrol 300 mg daily for 2 weeks.</description>
    <arm_group_label>Active First</arm_group_label>
    <arm_group_label>Placebo first</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 100 mg daily for 2 weeks followed by placebo 300 mg daily for 2 weeks.</description>
    <arm_group_label>Active First</arm_group_label>
    <arm_group_label>Placebo first</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects

          -  Age over 21 years old

          -  Body mass index less than 38 kg/m2

          -  Clinical stable type 2 diabetes mellitus

        Exclusion Criteria:

          -  Women who are lactating or pregnant

          -  Treatment with an investigations product within 30 days of screening

          -  Clinically evident major illness of other organ systems, including cancer, renal
             failure, or other conditions in the opinion of the investigators that would make
             clinical study inappropriate

          -  Liver transaminase levels greater than 3 times the upper limit of normal

          -  History of psychological illness or condition that would interfere with the subject's
             ability to understand the requirements of the study

          -  Vitamin supplements exceeding two times the recommended daily allowance

          -  Resveratrol or other dietary supplements except for a daily multivitamin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naomi Hamburg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boston University Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2013</study_first_submitted>
  <study_first_submitted_qc>June 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2013</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>endothelium</keyword>
  <keyword>mitochondria</keyword>
  <keyword>reactive oxygen species</keyword>
  <keyword>vascular biology</keyword>
  <keyword>arterial stiffness</keyword>
  <keyword>nitric oxide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Resveratrol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

